

The Efficacy of Vosevi in Treating DAA-experienced Patients

NCT06180590

Status	RECRUITING
Sponsor	The Third Affiliated Hospital of Guangzhou Medical University
Enrollment	200 participants

Plain Language Summary

This study evaluates Vosevi — a pill combining three antiviral medicines — for people who have Hepatitis C (HCV) and still have detectable virus despite having previously taken direct-acting antiviral (DAA) treatment. It looks at how well re-treatment works in these cases.

****You may be eligible if...****

- You are between 20 and 70 years old
- You have already taken a standard hepatitis C antiviral treatment
- Your blood test still shows active Hepatitis C virus (HCV-RNA positive)
- You are willing to take daily oral medication as prescribed

****You may NOT be eligible if...****

- You have never taken a prior hepatitis C antiviral treatment
- You have already achieved a cure (undetectable virus) with prior treatment
- You have severe liver disease such as decompensated cirrhosis
- You have serious interactions with the study medications

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (5)

- Age of 20-70 years.
- Accepted the standard direct antiviral agent before
- HCV-RNA still positive
- Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg) or Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin 500mg twice a day treatment for rescue therapy.
- The good compliance of patients.

Exclusion (4)

- Patients with antibodies against HIV, HBV, HDV, concretion or other forms of infectious disease.
- Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity.
- Concurrent treatment with glucocorticoids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators.
- Pregnancy.

Locations (1 total)

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

<https://clinicaltrials.gov/study/NCT06180590>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).